{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:11:59Z","timestamp":1771974719309,"version":"3.50.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2021-1086"],"award-info":[{"award-number":["075-15-2021-1086"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The COVID-19 pandemic has uncovered the high genetic variability of the SARS-CoV-2 virus and its ability to evade the immune responses that were induced by earlier viral variants. Only a few monoclonal antibodies that have been reported to date are capable of neutralizing a broad spectrum of SARS-CoV-2 variants. Here, we report the isolation of a new broadly neutralizing human monoclonal antibody, iC1. The antibody was identified through sorting the SARS-CoV-1 RBD-stained individual B cells that were isolated from the blood of a vaccinated donor following a breakthrough infection. <jats:italic>In vitro<\/jats:italic>, iC1 potently neutralizes pseudoviruses expressing a wide range of SARS-CoV-2 Spike variants, including those of the XBB sublineage. In an hACE2-transgenic mouse model, iC1 provided effective protection against the Wuhan strain of the virus as well as the BA.5 and XBB.1.5 variants. Therefore, iC1 can be considered as a potential component of the broadly neutralizing antibody cocktails resisting the SARS-CoV-2 mutation escape.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1442160","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T04:57:27Z","timestamp":1721365047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants"],"prefix":"10.3389","volume":"15","author":[{"given":"Sergey V.","family":"Guselnikov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin O.","family":"Baranov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey V.","family":"Kulemzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana N.","family":"Belovezhets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton N.","family":"Chikaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana V.","family":"Murasheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga Y.","family":"Volkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmila V.","family":"Mechetina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Najakshin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai A.","family":"Chikaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel P.","family":"Solodkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria V.","family":"Sergeeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander V.","family":"Smirnov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina A.","family":"Serova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg L.","family":"Serov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander G.","family":"Markhaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia V.","family":"Kononova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Y.","family":"Alekseev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina A.","family":"Gulyaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria M.","family":"Danilenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nariman R.","family":"Battulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Shestopalov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander V.","family":"Taranin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates","volume":"13","author":"Jones","year":"2021","journal-title":"Sci Transl Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41467-020-20602-5","article-title":"A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein","volume":"12","author":"Kim","year":"2021","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2078160","article-title":"Therapeutic monoclonal antibodies for COVID-19 management: an update","volume":"22","author":"Chavda","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112532","article-title":"Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination","volume":"42","author":"Ju","year":"2023","journal-title":"Cell Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41467-024-45171-9","article-title":"A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity","volume":"15","author":"de Campos-Mata","year":"2024","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.04.012","article-title":"An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2","author":"Focosi","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00744-2","article-title":"Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure","volume":"24","author":"Yang","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.16.589454","article-title":"A generalized framework to identify SARS-CoV-2 broadly neutralizing antibodies","author":"Jian","year":"2024","journal-title":"BioRxiv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41421-021-00340-8","article-title":"Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern","volume":"7","author":"Gorchakov","year":"2021","journal-title":"Cell Discovery"},{"key":"B19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3390\/jpm12060895","article-title":"VH3-53\/66-class rbd-specific human monoclonal antibody ib20 displays cross-neutralizing activity against emerging sars-cov-2 lineages","volume":"12","author":"Kulemzin","year":"2022","journal-title":"J Pers Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/vaccines12010055","article-title":"Hybrid immunity from Gam-COVID-Vac vaccination and natural SARS-CoV-2 infection confers broader neutralizing activity against omicron lineage VOCs than revaccination or reinfection","volume":"12","author":"Kulemzin","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1038\/s41467-023-40592-4","article-title":"Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history","volume":"14","author":"Hornsby","year":"2023","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2146538","article-title":"Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2","volume":"12","author":"Luo","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro775","article-title":"SARS\u2013beginning to understand a new virus","volume":"1","author":"Stadler","year":"2003","journal-title":"Nat Rev Microbiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning","volume":"329","author":"Tiller","year":"2008","journal-title":"J Immunol Methods"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2144\/btn-2019-0079","article-title":"A simple way to increase recovery of the expressed VH and VL genes in single-sorted human B cells","volume":"67","author":"Guselnikov","year":"2019","journal-title":"BioTechniques"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e28268","DOI":"10.1002\/jmv.28268","article-title":"Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines","volume":"95","author":"Luczkowiak","year":"2023","journal-title":"J Med Virol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1038\/s41467-020-19231-9","article-title":"Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation","volume":"11","author":"Hurlburt","year":"2020","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03817-4","article-title":"Broad sarbecovirus neutralization by a human monoclonal antibody","volume":"597","author":"Tortorici","year":"2021","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.06.438709","article-title":"Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape","author":"Starr","year":"2021","journal-title":"BioRxiv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm8143","article-title":"Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry","volume":"375","author":"Park","year":"2022","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111845","article-title":"Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents","volume":"41","author":"Cao","year":"2022","journal-title":"Cell Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa739","article-title":"CoV-AbDab: the coronavirus antibody database","volume":"37","author":"Raybould","year":"2021","journal-title":"Bioinformatics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/vaccines12020129","article-title":"Serial llama immunization with various SARS-CoV-2 RBD variants induces broad spectrum virus-neutralizing nanobodies","volume":"12","author":"Solodkov","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.30.596396","article-title":"Characterizing a lethal CAG-ACE2 transgenic mouse model for SARS-CoV-2 infection with using Cas9-enhanced nanopore sequencing","author":"Smirnov","year":"2024","journal-title":"BioRxiv"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3390\/pathogens11121461","article-title":"Genomic variability of SARS-CoV-2 omicron variant circulating in the Russian federation during early December 2021 and late January 2022","volume":"11","author":"Chernyaeva","year":"2022","journal-title":"Pathogens"},{"key":"B36","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s42003-023-05332-w","article-title":"SARS-CoV-2 antibodies recognize 23 distinct epitopic sites on the receptor binding domain","volume":"6","author":"Jiang","year":"2023","journal-title":"Commun Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201993","article-title":"Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo","volume":"218","author":"Sch\u00e4fer","year":"2021","journal-title":"J Exp Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03720-y","article-title":"In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains","volume":"596","author":"Chen","year":"2021","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.28.582613","article-title":"Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination","author":"Clark","year":"2024","journal-title":"BioRxiv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04441-6","article-title":"SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters","volume":"603","author":"Halfmann","year":"2022","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1320856","article-title":"SARS-CoV-2 omicron BA.5 and XBB variants have increased neurotropic potential over BA.1 in K18-hACE2 mice and human brain organoids","volume":"14","author":"Stewart","year":"2023","journal-title":"Front Microbiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2024.01.003","article-title":"SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequences","volume":"45","author":"Wang","year":"2024","journal-title":"Trends Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-023-01504-w","article-title":"SARS-CoV-2 evolution in the Omicron era","volume":"8","author":"Roemer","year":"2023","journal-title":"Nat Microbiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1442160\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T04:57:29Z","timestamp":1721365049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1442160\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2024.1442160"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1442160","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]},"article-number":"1442160"}}